Bisacodyl
Halflytely (bisacodyl) is a small molecule pharmaceutical. Bisacodyl was first approved as Halflytely on 2010-07-16. It is used to treat constipation in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bisacodyl
+
Polyethylene glycol 3350
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HALFLYTELY | Braintree Laboratories | N-021551 DISCN | 2010-07-16 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avedana gentle laxative | C200263 | 2024-01-04 |
| bisac-10 bisacodyl stimulant laxative | OTC monograph not final | 2023-04-28 |
| bisacody | OTC monograph not final | 2022-11-01 |
| bisacodyl | C200263 | 2024-10-17 |
| bisacodyl 5mg | C200263 | 2019-03-26 |
| bisacodyl laxative | C200263 | 2023-12-21 |
| c-lax laxative | C200263 | 2024-01-26 |
| conlax | OTC monograph not final | 2023-03-01 |
| cvs fast relief laxative | OTC monograph not final | 2014-10-03 |
| cvs gentle laxative | C200263 | 2024-02-05 |
Show 58 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| constipation | HP_0002019 | D003248 | K59.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | 3 | 5 | 8 | 8 | 24 |
| Colonoscopy | D003113 | — | — | — | — | 4 | 9 | 7 | 20 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | 1 | 3 | 5 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | 1 | 1 | 2 | 4 |
| Ileus | D045823 | — | — | 1 | — | — | 2 | — | 3 |
| Opioid-induced constipation | D000079689 | — | — | — | — | — | 1 | 1 | 2 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | 1 | — | 1 | — | 2 |
| Paralysis | D010243 | HP_0003470 | — | — | — | — | 1 | — | 1 |
| Intestinal neoplasms | D007414 | — | C26.0 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fecal incontinence | D005242 | — | R15 | — | 1 | 1 | — | 2 | 4 |
| Encopresis | D004688 | — | F98.1 | — | — | 1 | — | 2 | 3 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | — | 1 | — | 1 | 2 |
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | — | 1 | — | 1 | 2 |
| Adenoma | D000236 | — | — | — | — | 1 | — | 1 | 2 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | 1 | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | — | 1 |
| Treatment outcome | D016896 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
| Proctitis | D011349 | EFO_0005628 | K62.89 | — | 1 | — | — | — | 1 |
| Telangiectasis | D013684 | — | — | — | 1 | — | — | — | 1 |
| Radiation injuries | D011832 | — | — | — | 1 | — | — | — | 1 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | — | — | — | 1 |
| Alopecia | D000505 | HP_0002293 | L64 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonic polyps | D003111 | — | K63.5 | 1 | — | — | — | 1 | 2 |
| Adenomatous polyps | D018256 | — | D28 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonic neoplasms | D003110 | — | C18 | — | — | — | — | 2 | 2 |
| Colonic diseases | D003108 | — | — | — | — | — | — | 2 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | — | — | — | 1 | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
| Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 1 | 1 |
| Digestive system diseases | D004066 | HP_0011024 | K92.9 | — | — | — | — | 1 | 1 |
| Capsule endoscopy | D053704 | — | — | — | — | — | — | 1 | 1 |
| Hirschsprung disease | D006627 | EFO_0004241 | Q43.1 | — | — | — | — | 1 | 1 |
| Anorectal malformations | D000071056 | — | — | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bisacodyl |
| INN | bisacodyl |
| Description | Bisacodyl is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 603-50-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL942 |
| ChEBI ID | — |
| PubChem CID | 2391 |
| DrugBank | DB09020 |
| UNII ID | 10X0709Y6I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Bisacodyl
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,547 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,146 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use